Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: March 30th, 2010 - March 30th, 2011

Target Audience
This activity was developed for pharmacy directors, P&T Committee members, managed care pharmacists, oncology pharmacists, and other key stakeholders who wish to enhance their practical insight on the health system/regional variances in the delivery of care for multiple myeloma.

Learning Objectives
At the completion of this activity participants should be able to:

  • Identify the intersection of epidemiologic shifts in the multiple myeloma patient population, including new diagnostic measures, staging, and achieving value-based clinical treatment strategies
  • Discuss the treatment of the newly diagnosed patient, including review of appropriate agent selection based on recently presented clinical trials
  • Describe treatment strategies in the relapsed patient, including the improvement in survival in the maintenance setting
  • Examine regional/health system variations in healthcare delivery, including diagnosing, treatment, and coverage decisions for the patient with multiple myeloma


Registered Pharmacy Designation
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 2.0 contact hours (0.2 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-10-019-H01-P.

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.

Faculty Disclosures
Gary M. Owens, MD, is a Consultant to Asthmatx, Biosense Webster, Centocor-OrthoBiotech, Eli Lilly, Genentech, and Novartis.

Jatin Shah, MD is a consultant for Amgen, Celgene, and Millennium, and is on an advisory board for Novartis .

Rusty Crawford, RPh, BCOP has nothing to disclose.

Sin (Masha) Lam, PharmD, BCOP has nothing to disclose.

Stephanie Taber, PharmD, BCOP has nothing to disclose.

*Content will include non-FDA-approved uses.

The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Related Items
New Directions in the Treatment and Symptom Management of Multiple Sclerosis – Part 2
Gary M. Owens, MD, Samuel F. Hunter, MD, PhD
Interactive Learning published on June 13, 2013
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Emerging Treatments and Evolving Strategies for the Cost-Effective Management of Myelofibrosis
Gary M. Owens, MD, Alfonso Quintas-Cardama, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
Cases in Multiple Myeloma: The Role of Oncology Pharmacists on an Interprofessional Team to Improve Patient Care and Outcomes
Stephanie S. Minich, PharmD, BCOP
Supplements published on August 29, 2011
Optimizing New and Emerging Therapies for Treatment and Symptom Management of Multiple Sclerosis in Managed Care
Gary M. Owens, MD, Bruce L. Hughes, MD , Sonya J. Lewis, RPh, MBA
Supplements published on August 2, 2011
Wellness and Prevention in Chronic Disease Consensus Statement
Gary M. Owens, MD, Nirav R. Shah, MD, MPH, FACP, Michael McLean, RPh, MPA, Kip Piper, MA, FACHE, Doug Burgoyne, PharmD, John Fox, MD, Stacie Heller, Wayne M. Lednar, MD, PhD, Lynne Rothney-Kozlak, Scott R. Taylor, RPh, MBA, F. Randy Vogenberg, RPh, PhD
Supplements published on September 30, 2010
Highlights from ASCO 2010: An Update for Payers and Providers on Chronic Myelogenous Leukemia
Gary M. Owens, MD, Michael Mauro, MD
Supplements published on September 15, 2010
Recent Advances in the Treatment of Multiple Myeloma
Jonathan Kaufman, MD, Beth Faiman, RN, MSN, APRN, BC, AOCN, Stephanie S. Minich, PharmD, BCOP, James O. Armitage, MD
Supplements published on September 30, 2009
ASCO 2009 Highlights on Breast Cancer: A Payer's and Pharmacist's Perspective
Gary M. Owens, MD
Supplements published on September 15, 2009
Value-Based Oncology Benefit Design™ Balancing Cost, Quality, and Access in Cancer Care
Gary M. Owens, MD, Al B. Benson III, MD, FACP, Gary Rice, RPh, MS, MBA
Supplements published on June 30, 2009
Last modified: March 21, 2014